| SOLV |
Report |
Total revenue |
BEAT |
pred ~$2.180B vs. cons $2.155B |
MEDIUM |
| SOLV |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.930 vs. cons $1.905 |
MEDIUM |
| SOLV |
Report |
Dental Solutions revenue |
BEAT |
pred ~$384.0M vs. cons $378.0M |
MEDIUM |
| SOLV |
Guide |
Organic sales growth (FY26) |
UNCHANGED |
guide ~2%-3% vs. cons 2.76% |
MEDIUM |
| SOLV |
Guide |
Adjusted diluted EPS (FY26) |
UNCHANGED |
guide ~$6.40-$6.60 / ~$6.55 vs. cons $6.547 |
MEDIUM |
| SOLV |
Guide |
ERP timing / Q3 revenue (Q3 2026) |
LOWER |
guide ~Q3 reversal; pred ~$1.90B vs. cons $1.964B |
MEDIUM |
| SOLV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
LOW |
| SOLV |
Return |
5-day cumulative residual |
+2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — reduced versus the lone Archetype C precedent because expectations are elevated |
LOW |